It is also approved for people with a BMI of 27 kg/m2 or higher who have at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia
This is no small task for the NHS, and it will be difficult to provide the level of wraparound care seen in patients who took part in the clinical trial, which is likely necessary to achieve maximum health benefits. In June 2024, NICE recommended tirzepatide for managing overweight and obesity in draft guidance following positive results from clinical trials, results of which showed that patients lost an average of 20.9% of their bodyweight in 36 weeks
We thank Philip Creed, PhD, from Edanz ( for editing a draft of this manuscript
The SURMOUNT trials, evaluating tirzepatide for weight management in individuals without diabetes, further documented blood pressure effects
Compounded products have not undergone independent clinical trials establishing their safety, efficacy, or bioequivalence to the FDA-approved branded versions